Evaluation of protocols for the prevention of MTCT in HBV carrier mother.

JRCT ID: jRCTs031180137

Registered date:19/02/2019

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: HBV carrier
• Date of first enrollment: 31/03/2012
• Target sample size: 15
• Study type: Interventional
• Intervention(s): To prevent HBV mother-to-child transmission, HBIG is simultaneously administered both intramuscularly (200 units) and intravenously (500 units) after birth.

Outcome(s)

• Primary Outcome: The prohibition rates of mother-to-child transmission.
• Secondary Outcome: Alteration of HBsAb titer in baby after treatments.

Key inclusion & exclusion criteria

• Age minimum: >=
• Age maximum: < 1age old
• Gender: Both
• Include criteria: The baby from a HBV carrier mother

Exclude criteria

1. The baby from a mother who has HBV DNA negative with HBsAb positive.
2. Other treatments are given priority to the baby.

Related Information

• Primary Sponsor: Yamaguchi Koushi
• Secondary ID(s): Nil known